Atlas of Proteomic Technologies

State of High-Plex Plasma Proteomics, 2026

• No single platform dominates. Platform decisions should be driven by context(s) of use.
• Olink and SomaScan/SomaSeq are the most validated options with the deepest head-to-head evidence base, but show modest cross-platform protein correlation (median Spearman 0.33 for matched assays).
• Mass spectrometry platforms (Seer, Biognosys) offer unbiased discovery and peptide-level resolution, but require significantly higher bioinformatics investment and show higher CVs.
• Nomic nELISA is a low-cost entrant with calibrated quantification. Its primary published study profiled 7,392 cell culture samples at 191-plex in under a week. If the platform holds in plasma at scale, it would change the economics of population studies.
• NULISA fills a specialized niche: attomolar limits of detection and blood p-tau217 measurement (research use only), benchmarked against amyloid PET and Simoa, suit Alzheimer's and neuroinflammation studies.

• 1.For population-scale proteomics (>100,000 samples): evaluate Olink Explore HT or SomaSeq, with Nomic as a cost-efficient alternative and Seer as a scalable MS-based solution.
• 2.For unbiased discovery in large-scale plasma proteomics studies (10–100K samples): consider Seer Proteograph XT.
• 3.For targeted neuroscience or immune profiling studies: consider NULISA with p-tau217/Aβ panel.
• 4.For tissue analysis (e.g., brain samples): consider Biognosys TrueDiscovery (P2 enrichment) or comparable mass spec methods. Olink and SomaSeq can handle tissue homogenates, but MS is the gold standard.
• 5.For systematic PTM discovery (phosphoproteomics, ubiquitinomics, glycoproteomics): none of the evaluated platforms offer dedicated enrichment workflows. Consider Biognosys TrueDiscovery as the closest within-class MS option, or an orthogonal MS platform with IMAC enrichment (e.g., EasyPhos + Spectronaut).